Lumara Health Research Grants in Prematurity

| Community and Family Health Funding

Keywords:

Sponsor     

  • AMAG Pharmaceuticals
  • Lumara Health

Amount

Upper  $75,000USD

NHGRI intends to commit $500,000 in each of FY 2016-2018 to fund 1-2 new awards per year. The actual number of awards and amount are contingent on NIH appropriations, and the submission of a sufficient number of meritorious applications.

An applicant may request direct costs of up to $200,000 per year and no more than $400,000 for the entire budget period. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

The scope of the proposed project should determine the project period. The maximum project period is 3 years.

 Abstract

Lumara Health, a division of AMAG Pharmaceuticals, announces available 2016 research grants to address prematurity and improve neonatal health. As a division of AMAG Pharmaceuticals, Lumara Health is committed to making a meaningful difference in the lives of mothers and families. Based in Waltham, Massachusetts, the company supports research to reduce premature birth and improve the health of the neonates and infants in the United States. Consideration will be given to basic or clinical research in maternal, fetal and neonatal/infant health. Applicants should submit proposals focused on reducing premature birth and/or improving the health of the neonates and infants in the United States.

Upcoming Deadlines

31 Jul 2016 (Confirmed) – Application (Sponsor deadline – required)

For more information visit http://pivot.cos.com/funding_opps/166318